{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-025649","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.358814+00:00","generated_at":"2026-05-16T06:59:04.909310+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CalciMedica discontinues Phase 2 KOURAGE trial of Auxora in AKI after IDMC safety concern","bullets":["IDMC identified a safety concern requiring re-evaluation of study design, particularly enrollment criteria.","No treatment-related deaths or SAEs requiring expedited FDA reporting in the trial.","Company plans comprehensive review of unblinded data to inform possible future AKI trials.","CEO reaffirms optimism for Auxora in acute pancreatitis; pivotal trial design expected H1 2026.","Also advancing second CRAC inhibitor CM5480 for pulmonary arterial hypertension."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-025649","json":"https://secwatch.observer/filing/0001193125-26-025649.json","markdown":"https://secwatch.observer/filing/0001193125-26-025649.md","text":"https://secwatch.observer/filing/0001193125-26-025649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526025649/0001193125-26-025649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526025649/d55769d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:59:04.909310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}